Indian Patent Office Rejects TB Drug Patent, Boosting Push For Affordable MDR-TB Treatment
The Indian Patent Office rejected TB Alliance’s patent application for a combination antibacterial regimen after objections over novelty and inventive step. Patient rights activists welcomed the decision, citing affordable access to BPaL medicines. Mumbai recorded 4,080 drug-resistant TB cases in 2025, according to BMC data.
Read the full report on The Free Press Journal
Story file
- Section
- India
- Places
- Maharashtra
- First reported by
- The Free Press Journal
- Reporter
- amit srivastava
- Published
- Wednesday, 28 October 2026, 8:21 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from The Free Press Journal with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
